Cisplatin and carboplatin result in similar gonadotoxicity in immature human testis with implications for fertility preservation in childhood cancer.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
04 12 2020
Historique:
received: 22 07 2020
accepted: 06 11 2020
entrez: 4 12 2020
pubmed: 5 12 2020
medline: 12 2 2021
Statut: epublish

Résumé

Clinical studies indicate chemotherapy agents used in childhood cancer treatment regimens may impact future fertility. However, effects of individual agents on prepubertal human testis, necessary to identify later risk, have not been determined. The study aimed to investigate the impact of cisplatin, commonly used in childhood cancer, on immature (foetal and prepubertal) human testicular tissues. Comparison was made with carboplatin, which is used as an alternative to cisplatin in order to reduce toxicity in healthy tissues. We developed an organotypic culture system combined with xenografting to determine the effect of clinically-relevant exposure to platinum-based chemotherapeutics on human testis. Human foetal and prepubertal testicular tissues were cultured and exposed to cisplatin, carboplatin or vehicle for 24 h, followed by 24-240 h in culture or long-term xenografting. Survival, proliferation and apoptosis of prepubertal germ stem cell populations (gonocytes and spermatogonia), critical for sperm production in adulthood, were quantified. Cisplatin exposure resulted in a significant reduction in the total number of germ cells (- 44%, p < 0.0001) in human foetal testis, which involved an initial loss of gonocytes followed by a significant reduction in spermatogonia. This coincided with a reduction (- 70%, p < 0.05) in germ cell proliferation. Cisplatin exposure resulted in similar effects on total germ cell number (including spermatogonial stem cells) in prepubertal human testicular tissues, demonstrating direct relevance to childhood cancer patients. Xenografting of cisplatin-exposed human foetal testicular tissue demonstrated that germ cell loss (- 42%, p < 0.01) persisted at 12 weeks. Comparison between exposures to human-relevant concentrations of cisplatin and carboplatin revealed a very similar degree of germ cell loss at 240 h post-exposure. This is the first demonstration of direct effects of chemotherapy exposure on germ cell populations in human foetal and prepubertal testis, demonstrating platinum-induced loss of all germ cell populations, and similar effects of cisplatin or carboplatin. Furthermore, these experimental approaches can be used to determine the effects of established and novel cancer therapies on the developing testis that will inform fertility counselling and development of strategies to preserve fertility in children with cancer.

Sections du résumé

BACKGROUND
Clinical studies indicate chemotherapy agents used in childhood cancer treatment regimens may impact future fertility. However, effects of individual agents on prepubertal human testis, necessary to identify later risk, have not been determined. The study aimed to investigate the impact of cisplatin, commonly used in childhood cancer, on immature (foetal and prepubertal) human testicular tissues. Comparison was made with carboplatin, which is used as an alternative to cisplatin in order to reduce toxicity in healthy tissues.
METHODS
We developed an organotypic culture system combined with xenografting to determine the effect of clinically-relevant exposure to platinum-based chemotherapeutics on human testis. Human foetal and prepubertal testicular tissues were cultured and exposed to cisplatin, carboplatin or vehicle for 24 h, followed by 24-240 h in culture or long-term xenografting. Survival, proliferation and apoptosis of prepubertal germ stem cell populations (gonocytes and spermatogonia), critical for sperm production in adulthood, were quantified.
RESULTS
Cisplatin exposure resulted in a significant reduction in the total number of germ cells (- 44%, p < 0.0001) in human foetal testis, which involved an initial loss of gonocytes followed by a significant reduction in spermatogonia. This coincided with a reduction (- 70%, p < 0.05) in germ cell proliferation. Cisplatin exposure resulted in similar effects on total germ cell number (including spermatogonial stem cells) in prepubertal human testicular tissues, demonstrating direct relevance to childhood cancer patients. Xenografting of cisplatin-exposed human foetal testicular tissue demonstrated that germ cell loss (- 42%, p < 0.01) persisted at 12 weeks. Comparison between exposures to human-relevant concentrations of cisplatin and carboplatin revealed a very similar degree of germ cell loss at 240 h post-exposure.
CONCLUSIONS
This is the first demonstration of direct effects of chemotherapy exposure on germ cell populations in human foetal and prepubertal testis, demonstrating platinum-induced loss of all germ cell populations, and similar effects of cisplatin or carboplatin. Furthermore, these experimental approaches can be used to determine the effects of established and novel cancer therapies on the developing testis that will inform fertility counselling and development of strategies to preserve fertility in children with cancer.

Identifiants

pubmed: 33272271
doi: 10.1186/s12916-020-01844-y
pii: 10.1186/s12916-020-01844-y
pmc: PMC7716476
doi:

Substances chimiques

Carboplatin BG3F62OND5
Cisplatin Q20Q21Q62J

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

374

Subventions

Organisme : Wellcome Trust
ID : 098522
Pays : United Kingdom
Organisme : Children with Cancer UK
ID : 15-198
Pays : International
Organisme : Medical Research Council
ID : MR/R006237/1
Pays : United Kingdom
Organisme : Birgitta and Carl-Axel Rydbeck's Research Grant
ID : 2020-00348
Pays : International
Organisme : Medical Research Council
ID : G1100357
Pays : United Kingdom
Organisme : Swedish Childhood Cancer Foundation
ID : TJ20200023
Pays : International
Organisme : Medical Research Council
ID : MR/S017151/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N022556/1
Pays : United Kingdom

Références

Biol Reprod. 2004 Dec;71(6):2012-21
pubmed: 15317684
Cell Stem Cell. 2012 Nov 2;11(5):715-26
pubmed: 23122294
Environ Health Perspect. 2015 Mar;123(3):223-30
pubmed: 25514601
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):632-8
pubmed: 22420962
J Clin Invest. 2008 Apr;118(4):1479-90
pubmed: 18340380
Int J Gynecol Cancer. 2010 Dec;20(9):1456-64
pubmed: 21307819
Med Pediatr Oncol. 1989;17(5):409-13
pubmed: 2507885
J Clin Endocrinol Metab. 2012 Mar;97(3):E341-8
pubmed: 22238399
Hum Reprod. 2015 Nov;30(11):2463-75
pubmed: 26358785
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
Eur J Cancer Clin Oncol. 1985 May;21(5):601-5
pubmed: 2408897
Best Pract Res Clin Endocrinol Metab. 2018 Aug;32(4):355-372
pubmed: 30086863
Sci Rep. 2018 Jan 29;8(1):1773
pubmed: 29379115
Sci Transl Med. 2015 May 20;7(288):288ra80
pubmed: 25995226
Hum Reprod. 2010 Oct;25(10):2405-14
pubmed: 20683063
Lancet Oncol. 2014 Oct;15(11):1215-23
pubmed: 25239573
J Cancer Surviv. 2014 Sep;8(3):437-47
pubmed: 24711092
Hum Reprod. 2015 Oct;30(10):2351-63
pubmed: 26251460
Dalton Trans. 2018 May 15;47(19):6645-6653
pubmed: 29632935
J Exp Med. 2017 Jun 5;214(6):1631-1641
pubmed: 28461596
J Clin Oncol. 2009 May 10;27(14):2308-18
pubmed: 19364948
Cell Res. 2018 Dec;28(12):1141-1157
pubmed: 30315278
Lancet Diabetes Endocrinol. 2015 Jul;3(7):556-67
pubmed: 25873571
Environ Health Perspect. 2018 Apr 16;126(4):047006
pubmed: 29665328
Cell Rep. 2018 Nov 6;25(6):1650-1667.e8
pubmed: 30404016
Lancet Oncol. 2016 May;17(5):567-76
pubmed: 27020005
Hum Reprod. 2008 Dec;23(12):2755-65
pubmed: 18694875
Reproduction. 2019 Nov;158(5):F1-F14
pubmed: 30844751
Cell Stem Cell. 2020 Feb 6;26(2):262-276.e4
pubmed: 31928944
Lancet Oncol. 2017 Feb;18(2):e75-e90
pubmed: 28214419
Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23
pubmed: 15607932
Am J Obstet Gynecol. 2015 Aug;213(2):206.e1-5
pubmed: 25731691
Mol Hum Reprod. 2020 Mar 26;26(3):129-140
pubmed: 31953538
Hum Reprod. 2019 Jun 4;34(6):966-977
pubmed: 31111889
Anticancer Res. 2001 Jul-Aug;21(4A):2703-7
pubmed: 11724343
Hum Reprod Update. 2019 Jul 1;25(4):397-421
pubmed: 30869130
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Drug Metab Dispos. 2010 Oct;38(10):1623-35
pubmed: 20606001

Auteurs

Melissa D Tharmalingam (MD)

MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK.
KK Women's and Children's Hospital, Bukit Timah Rd, 100, Singapore, 229899, Singapore.

Gabriele Matilionyte (G)

MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK.

William H B Wallace (WHB)

Edinburgh Royal Hospital for Sick Children, 9 Sciennes Road, Edinburgh, EH9 1LF, Scotland, UK.

Jan-Bernd Stukenborg (JB)

NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

Kirsi Jahnukainen (K)

NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Division of Haematology-Oncology and Stem Cell Transplantation, Children's Hospital, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland.

Elizabeth Oliver (E)

NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

Anne Goriely (A)

Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX39DS, UK.

Sheila Lane (S)

Department of Paediatrics and Child Health, Oxford University Hospitals NHS Foundation Trust, and Nuffield Department of Womens and Reproductive Health, University of Oxford, Oxford, UK.

Jingtao Guo (J)

Section of Andrology, Division of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.
Howard Hughes Medical Institute, Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.

Bradley Cairns (B)

Howard Hughes Medical Institute, Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.

Anne Jorgensen (A)

Department of Growth and Reproduction, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, 2100, Copenhagen, Denmark.

Caroline M Allen (CM)

Biomedical Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK.

Federica Lopes (F)

MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK.

Richard A Anderson (RA)

MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK.

Norah Spears (N)

Biomedical Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK.

Rod T Mitchell (RT)

MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK. rod.mitchell@ed.ac.uk.
Edinburgh Royal Hospital for Sick Children, 9 Sciennes Road, Edinburgh, EH9 1LF, Scotland, UK. rod.mitchell@ed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH